ReviewHuman vaccines & immunotherapeutics2017
A critical appraisal of 'Shingrix', a novel herpes zoster subunit vaccine (HZ/Su or GSK1437173A) for varicella zoster virus.
Review in Human vaccines & immunotherapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 64 citations in OpenAlex.
- Development of mRNA vaccines against herpes zoster.Human vaccines & immunotherapeutics · 2026Review
- Rescuing age-associated vaccine hyporesponsiveness in murine and nonhuman primate models with an immunostimulatory vaccine adjuvant.Human vaccines & immunotherapeutics · 2026Article
- Article
- A fresh look at varicella vaccination.Human vaccines & immunotherapeutics · 2025Review
- Unilateral uveitis following adjuvanted Varicella-Zoster subunit vaccine in a patient with previously resolved Varicella Zoster acute retinal necrosis.Journal of ophthalmic inflammation and infection · 2025Article
- Varicella-Zoster Virus Infection and Varicella-Zoster Virus Vaccine-Related Ocular Complications.Vaccines · 2025Review
- Research Progress on Varicella-Zoster Virus Vaccines.Vaccines · 2025Review
- Enantioselective Synthesis of β-l-5-[(The Journal of organic chemistry · 2024Article
- Vaccines and the Eye: Current Understanding of the Molecular and Immunological Effects of Vaccination on the Eye.International journal of molecular sciences · 2024Review
- Herpes zoster ophthalmicus following recombinant zoster vaccine: A case report and brief literature review.IDCases · 2024Article
- Ocular Inflammation Post-Vaccination.Vaccines · 2023Review
- Research Progress of Aluminum Phosphate Adjuvants and Their Action Mechanisms.Pharmaceutics · 2023Review
- Status of Herpes Zoster and Herpes Zoster Vaccines in 2023: A position paper.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2023Review
- Prodrug Strategies for the Development of β-l-5-((Journal of medicinal chemistry · 2023Article
- Review
- A Guide to Preclinical Models of Zoster-Associated Pain and Postherpetic Neuralgia.Current topics in microbiology and immunology · 2023Review
- Urgency and necessity of Epstein-Barr virus prophylactic vaccines.NPJ vaccines · 2022Review
- Glycoconjugates: Synthesis, Functional Studies, and Therapeutic Developments.Chemical reviews · 2022Review
- External Therapy of Chinese Medicine for Herpes Zoster: A Systematic Review and Meta-Analysis.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Uveitis reactivation following recombinant zoster vaccination.American journal of ophthalmology case reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
HZ/Su, branded as 'Shingrix', is one of the newest vaccines to be submitted for multi-national regulatory approval. It is targeted to prevent shingles, a global concern with aging populations. A live attenuated vaccine for shingles has been available for over a decade, however it is contraindicated in specific subgroups of people, and there are added concerns regarding long-term immunogenicity. HZ/Su is the first subunit vaccine developed to protect against shingles. This paper provides a critical appraisal of current evidence regarding HZ/Su.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.